Join to View Full Profile
160 East 34th Street8th FloorNew York, NY 10016
Phone+1 212-731-5662
Dr. Wong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kwok Kin Wong is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, and North Shore Medical Center. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice 21 years. He specializes in hematologic oncology.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1996 - 1998
Columbia University Vagelos College of Physicians and SurgeonsClass of 1996
Certifications & Licensure
NY State Medical License 2016 - 2026
MA State Medical License 1998 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2008
Publications & Presentations
PubMed
- 1 citationsDiscovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C.Anna E Maciag, James P Stice, Bin Wang, Alok K Sharma, Albert H Chan
Cancer Discovery. 2025-03-03 - Characterization of tumour heterogeneity through segmentation-free representation learning on multiplexed imaging data.Jimin Tan, Hortense Le, Jiehui Deng, Yingzhuo Liu, Yuan Hao
Nature Biomedical Engineering. 2025-03-01 - In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.Justine Habault, Jennifer L Franco, Susan Ha, Jeffry A Schneider, Maud Voisin
The Prostate. 2025-02-16
Grant Support
- Targeting molecular mechanisms of the adeno-to-squamous transition in non-small cell lung cancer treatment adaptationNEW YORK UNIVERSITY SCHOOL OF MEDICINE2025–2029
- Targeting cell state transitions driving resistance to KRAS inhibitors in lung cancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2024–2029
- Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2024–2029
- Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung CancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2025
- Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung CancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2025
- Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung CancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2025
- Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung CancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
